Format

Send to

Choose Destination

See 1 citation found using an alternative search:

Eur J Obstet Gynecol Reprod Biol. 2017 May;212:132-139. doi: 10.1016/j.ejogrb.2017.03.029. Epub 2017 Mar 19.

A model to evaluate the costs and clinical effectiveness of human papilloma virus screening compared with annual papanicolaou cytology in Germany.

Author information

1
Department of Gynaecology and Obstetrics, Klinikum Wolfsburg, Sauerbruchstrasse 7, 38440 Wolfsburg, Germany. Electronic address: k.u.petry@klinikum.wolfsburg.de.
2
Institute for Health Care Management and Research, Thea-Leymann-Strasse 9, 45127 Essen, Germany.

Abstract

OBJECTIVES:

We modelled human papilloma virus (HPV) primary screening scenarios compared with Pap cytology to evaluate clinical effectiveness and projected annual costs in Germany.

STUDY DESIGN:

A Markov cohort model was built to compare the budget impact of annual Pap cytology with different 5-yearly HPV screening scenarios: (1) a positive HPV test followed by Pap cytology; (2) a positive HPV test followed by p16/Ki-67 dual-stained cytology; (3) a positive HPV test followed by colposcopy if HPV-16/18-positive or p16/Ki-67 dual-stained cytology if positive for other subtypes; (4) co-testing with HPV and Pap. Screening scenarios were based on a 10-year horizon.

RESULTS:

All HPV screening scenarios in the model were associated with fewer deaths from missed diagnosis of cervical cancer compared with Pap screening; 10-year totals n=172-344 (1.5-3 per 100,000) versus n=477 (4.1 per 100,000), respectively. Total annual costs were lower with HPV screening than Pap cytology. The projected average annual cost for HPV screening ranged from €117 million to €136 million compared with €177 million for Pap screening, representing annual savings of €41-60 million. The greatest clinical impact was achieved with primary HPV screening (with genotyping) followed by colposcopy for HPV 16/18-positive women or p16/Ki-67 dual-stained cytology for women positive for other HPV subtypes.

CONCLUSION:

Screening strategies including primary HPV testing for high-risk subtypes (HPV-16/18) in conjunction with p16/Ki-67 dual-stained cytology can improve the detection of cervical cancer at a lower total annual cost than conventional Pap cytology screening.

KEYWORDS:

Human papilloma virus; Screening cervical cancer

PMID:
28363186
DOI:
10.1016/j.ejogrb.2017.03.029
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center